In addition to each of the factors that govern the identification of a successful oncology drug
candidate, drug discovery aimed at treating neurological cancer must also consider the …

Introduction: Alvocidib, which has orphan drug designation in chronic lymphocytic leukemia
(CLL) from the FDA and the EMA, is a plant-derived semisynthetic flavone that acts as a …

Irreversible inhibition of transcriptional cyclin-dependent kinases (CDKs) provides a
therapeutic strategy for cancers that rely on aberrant transcription; however, lack of …

Ribociclib is a novel cyclin-dependent kinase (CDK) 4 and 6 selective inhibitor that recently
gained breakthrough therapy status and global approval for advanced breast cancer …

Despite decades of clinical trials for diffuse intrinsic pontine glioma (DIPG), patient survival
does not exceed 10% at two years post-diagnosis. Lack of benefit from systemic …

Background: Cisplatin, a powerful antitumor agent, causes formation of DNA adducts, and
activation of apoptotic pathways. Presently, cisplatin resistance develops in up to 70% of …

Brivanib, a promising tyrosine kinase inhibitor, is currently undergoing advanced stages of
clinical evaluation for solid tumor therapy. In this work, we investigated possible interactions …

Computer-aided pattern analysis (C@ PA) was recently presented as a powerful tool to
predict multitarget ABC transporter inhibitors. The backbone of this computational …

Gastric cancer remains a big health problem in China. Gastric cancer cells contain a small
subpopulation of cells that exhibit capabilities of differentiation and tumorigenicity. A putative …

Abstract Cyclin-dependent kinases (CDK), a family of heterodimeric kinases that play central
roles in regulation of cell cycle progression and transcription, have garnered attention in …